We are proud to present this second annual issue of the Annals of Surgical Oncology (ASO) covering the 12th Annual meeting of the American Society of Breast Surgeon (ASoBRS) meeting. The conference was held in Washington, DC, from April 28 to May 2, 2011, with over 1,200 attendees. The meeting provided updates for attendees on recent advances and technological developments in the management of breast disease as well as giving us glimpses into the future. The program covered a broad range of topics including what is new in breast surgery, intraoperative radiation, triple negative tumors, management of the axilla with positive sentinel node, breast cancer classification and staging in the molecular era, and management of high-risk lesions. This issue includes invited papers from educational material presented at the meeting and competitively reviewed original manuscripts on subjects ranging from surgical techniques, cost-effectiveness, ductal evaluation methods, breast imaging modalities, nipplesparing mastectomy, and other important subjects.
Minimally invasive approaches to diagnosis and treatment of surgical diseases have rapidly accelerated in the past decade. Selected patients now have their aortic valves replaced percutaneously; coronary arteries, aortic aneurysms, and carotid arteries stented; and laparoscopic minimal incision surgery is routinely performed for a wide array of intraabdominal and intrathoracic procedures. Ablation using energy sources that include radiofrequency ablation, focused ultrasound, and cryotherapy are routinely being used to treat prostate cancer and liver and lung metastases. Open surgical diagnostic excisional breast biopsy is becoming a historical footnote as most patients now undergo image-guided biopsies. The ASoBRS has provided the leadership in training surgeons to master ultrasound-guided and stereotactic biopsies. We are on the threshold of beginning to utilize percutaneous and transcutaneous in the treatment of breast cancer.
In this issue of ASO, there are three important articles that illuminate this trend. Whitworth describes a large experience with the IPEX intact specimen excision for definitive diagnosis of high-risk lesions. 1 This device overcomes the problem of multiple core specimens and allows specimen margin evaluation. 1 It has the potential to avoid secondary surgical excision for a substantial number of patients with mammographically or sonographically detected lesions. Brenin 2 describes the technique of focused ultrasound ablation for the treatment of small, well-defined breast cancers. Several single-institution reports show impressive efficacy. 3, 4 A multicenter trial is in development. Last, Klimberg et al. 5 present an exciting pilot study showing the feasibility of percutaneous excision followed by radiofrequency ablation for local control in small breast cancers. This is an ablate-and-resect study that is an incremental step toward a nonexcisional method. This is the logical extension of Klimberg's work with intraoperative radiofrequency ablation at the time of lumpectomy to reduce reoperation for margin involvement and potentially reduce radiation requirements. 6 This method is now being studied with a multicenter (ABLATE) trial (http://www.uams.edu/breastteam/).
Intuitively, percutaneous and transcutaneous treatment of breast cancer are appealing. For the surgical community to adopt new therapeutic approaches, however, the end result needs to be rigorously compared to the current standard of care. Lumpectomy through a skin incision over the tumor has proven its reliability, efficacy, and costeffectiveness in treating breast cancers.
END POINTS OF MODALITIES
We have to critically evaluate these new modalities from different aspects. First and foremost, the efficacy and safety of new modalities has to be confirmed and compared to the current standard as care. The specific end points to be compared are local control of the primary tumor, indications, side effects, and cosmetic outcome.
Local Control of Primary Tumor
We have to establish the ability of percutaneous and transcutaneous technique to adequately ablate the breast primary with sufficient margins of safety that minimize residual viable tumor cells. The ultimate end point would be the recurrence rate of the breast primary in the tumor bed or in the same quadrant as the original breast cancer. The current rate of local recurrence after breast conservation is close to 6%. 7 To collect data on local recurrence rate may require many years of follow-up, particularly that 30% of local recurrence that occurs beyond 10 years after surgery. 8 A common surrogate currently used by many researchers exploring these new treatments has been based on treating the tumor transcutaneously or percutaneously, followed by standard resection of the primary tumor. Pathologic evaluation of the treated tissue may shed light on the extent of disruption of the tumor and the volume of residual disease. Such approach may over-or underestimate the efficacy of these new modalities in locally controlling the primary tumor, and the ultimate answer remains assessing the shortand long-term local recurrence rate.
Indications
Percutaneous and transcutaneous treatment will need to be validated in specific types of breast cancers. The amount and type of energy used to achieve successful ablation of the primary tumor may vary between patients and tumors. The surgeon will have to factor the size and location of the primary tumor (superficial vs. deep), the infiltrative nature of the malignancy (relatively defined borders vs. extensive infiltration of the borders), and the consistency of the surrounding tissue (fatty vs. glandular). The proposed treatments are initially evaluated in small low-risk lesions with a relatively low risk of local recurrence. After the success of any new therapeutic option with early breast cancer, it behooves clinical researchers to pursue their evaluations in larger and more complex cancers. The potential to downsize these tumors with preoperative chemotherapy may make ablation possible. Testing the efficacy of a new treatment in different scenarios will help define its scope and limitation.
Side Effects
Percutaneous and transcutaneous ablation is achieved by delivering a source of energy, such as radiofrequency, laser beam, heat, and ultrasound waves, to the primary tumor or by freezing it. The ablative process destroys the tumor cells and the surrounding tissue. The extent of disruption may vary between patients depending on tumor and host factors. The short-and long-term side effects need to be determined; it is of paramount importance to carefully evaluate long-term safety issues relating to underlying chest wall and adjacent neurovascular structures. The possible complications of skin loss, infection, seroma, or hematoma need to be prospectively evaluated.
Cosmetic Outcome
Part of the interest in these new modalities lies in the improved cosmesis, the result of minimal or no cutaneous scarring. The cosmetic result depends not only on the cutaneous scar, however. With the development of neoadjuvant chemotherapy and oncoplastic techniques, surgeons have been able to minimize breast deformity and achieve excellent cosmetic outcome. With the ability to move breast tissue to close the resection defect and to combine plastic surgical procedures with oncologic resection, patients frequently prefer the operated breast when compared to the contralateral side. With these minimalaccess therapies, the tumor is ablated, and the tissue is left behind to necrose, liquefy, and resolve without any repair of the resultant defect. The final cosmetic result, particularly with larger tumors, remains unclear. Thus it is important to adequately measure the cosmetic outcome with transcutaneous and percutaneous procedures.
EASE OF IMPLEMENTATION
The skills that the surgeon has to acquire have to be defined and taught through specific training courses: image-guided intervention, delivery of energy source, and assessment of response through imaging. It is important to evaluate the facility of acquiring the skills required by the surgeons and their learning curves. The implementation of sentinel node biopsy has been a good example of such an exercise.
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Patient Perspectives
One important criterion for adoption of a new therapeutic modality is consumer opinion. Patient feedback is extremely important in helping clinicians define the superiority of one treatment option versus another. The transcutaneous treatment HUCFA requires the patient to lie prone and still for a long time, depending on tumor size. 2 How well that would be tolerated? How safe is sedation in the prone position? The level of intraoperative and postoperative pain associated with these procedure needs to be measured and compared to lumpectomy. Currently a lumpectomy could be performed under local anesthesia with or without sedation and is usually associated with minimal postoperative pain that is controlled with mild analgesics.
Cost-Effectiveness
Any new treatment modality has its expenses, such as instruments, machinery, imaging, operating room time, and technical staff. In our current era of cost containment, as a surgical community, we have to be conscious of the cost of new treatments. We have to justify the extra expense of implementing any new modality. Breast cancer remains the most common cancers in women, with approximately 200,000 (in situ and invasive) operable cases per year in the United States alone. An addition of $3,000-$5,000 to the management of a single case will result in an increment of $600 million to $1 billion per year to the nation's health care expenses. Our current spending budget is $793 billion per year. One billion dollars may seem miniscule; but does the new modality justify the extra expense? 11 
CONCLUSION
Progress is extremely important. The breast surgical community has to be bold, think outside the box, and develop new and better therapeutic options for caring for our patients with breast disease. New modalities must continue to be critically and rigorously evaluated before they are adopted as a standard of care.
